Featured

Home>Featured
Feb 8 2024

Halberd and Mississippi State University to Commence Stage II Advanced TBI Nasal Spray Testing

By |2024-02-08T08:07:03-05:00February 8th, 2024|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA February 8, 2024 – Halberd Corporation’s (OTC-PINK: "HALB”) Traumatic Brain Injury (TBI) mitigating nasal spray testing protocols at Mississippi State University (MSU) were approved by the Institutional Animal Care and Use Committee. Dr. Russell Carr, the Primary Investigator, initiated preparations for this extension of the successful Phase #1 pilot test program, completed ...

Jan 11 2024

Halberd Corporation 2023 Year-End CEO Update and 2024 Goals

By |2024-01-10T20:13:22-05:00January 11th, 2024|Featured, Investor News, News|0 Comments

Jackson Center, PA, January 11, 2024 -- Halberd Corporation (OTC: HALB) made significant advances in its technology development and accomplished major business goals during the second half of 2023. 2023 ACHIEVEMENTS Halberd received from the CDC two sets of antibiotic resistant bacteria and fungi (a total of 60 samples) on which to test its proprietary ...

Jan 9 2024

Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX

By |2024-01-10T05:12:05-05:00January 9th, 2024|Featured, Investor News, Press Releases|0 Comments

Athena will employ its successful history of securing government contracts, spearheading such initiatives Jackson Center, PA January 9, 2024 – Halberd Corporation (OTC-PINK: "HALB”) is thrilled to declare the formalization of a profitable revenue-sharing accord with Athena GTX, Inc., of Johnston, Iowa, (www.athenagtx.com).  Athena GTX is a private enterprise specializing in providing medical care solutions ...

Dec 13 2023

Halberd Corporation Signs Multi-Faceted Agreement with CrodenHealth.com

By |2023-12-12T18:17:31-05:00December 13th, 2023|Featured, Investor News, News, Press Releases|0 Comments

Peter Croden, CrodenHealth Chairman, previously executive with Pharmacia & Upjohn (Pfizer), Upjohn Canada, Upjohn Global Animal Health, NephRx, and Parnell Pharmaceuticals Holdings, Ltd. Endeavors to move Halberd forward Jackson Center, PA December 13, 2023 – Halberd Corporation (OTC-PINK: "HALB”) and CrodenHealth.com of Canada agree to produce, market, sell and distribute Halberd’s patented low dose naltrexone ...

Nov 15 2023

Halberd Corporation Plans to Extend Research Partnership with Mississippi State University

By |2023-11-14T18:09:30-05:00November 15th, 2023|Featured, Investor News, News, Press Releases|0 Comments

MSU Research for Halberd to Transcend the TBI Nasal Spray Jackson Center, PA November 15, 2023 – Halberd Corporation (OTC-PINK: "HALB”) is in talks with Mississippi State University (MSU) to extend its original six-month research arrangement by an additional two years, encompassing yet-to-be defined projects. This decision stems from MSU's exceptional performance in the recent ...

Oct 10 2023

Hartman, CEO and Dr. Felder, CTO of Halberd Corp Featured on The Street Reports Podcast

By |2023-10-09T16:58:07-04:00October 10th, 2023|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, October 10, 2022 – Halberd Corporation (OTC-PINK: "HALB”) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr Mitchell S. Felder were recently interviewed on “The Street Reports Podcast” to update the public on several of the company’s important projects: The significant results to-date of Halberd’s proprietary nasal spray testing ...

Sep 6 2023

Astounding Early Test Results of Halberd’s Traumatic Brain Injury (TBI) Project at Mississippi State University (MSU)

By |2023-09-06T05:46:15-04:00September 6th, 2023|Featured, Investor News, Medical, News, Press Releases|0 Comments

Anecdotal Results of Halberd’s Nasal Spray Reveals Demonstrably Significant Reduction of Traumatic Brain Injury Markers Jackson Center, PA September 6, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) research at Mississippi State University (MSU) has shown significant reduction in two key markers of traumatic brain injury (TBI) in early testing of Halberd’s patent-pending nasal spray to mitigate ...

Aug 22 2023

Halberd’s Successful Completion of Sampling Phase Marks Major Milestone for Project at Mississippi State University (MSU)

By |2023-08-21T18:31:47-04:00August 22nd, 2023|Featured, Investor News, News, Press Releases|0 Comments

Novel Nasal Spray for Traumatic Brain Injury Effects Poised to Demonstrate Efficacy in Patent-Pending Product Jackson Center, PA August 22, 2023 – Halberd Corporation (OTC-PINK: "HALB”) announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects.  This enables MSU to proceed with its pre-clinical model ...

Aug 14 2023

Halberd-Mississippi State University (MSU) Testing of TBI Nasal Spray Progresses

By |2023-08-13T19:31:35-04:00August 14th, 2023|Featured, Investor News, News|0 Comments

Scientific Paper Presented at Research Symposium Jackson Center, PA August 14, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) Traumatic Brain Injury (TBI) mitigation research on Halberd’s patent-pending nasal spray continues at Mississippi State University (MSU). MSU students, Jourdan, L.K., Broadaway, S. Cassen, et. al. authored and presented a paper on this project at the recent Mississippi ...

Jul 20 2023

Halberd Corporation 2Q23 CEO Letter

By |2023-07-19T20:54:59-04:00July 20th, 2023|Featured, Investor News, Update Letter|0 Comments

Jackson Center, PA, July 20, 2023 -- Halberd Corporation (OTC: HALB). During the second quarter 2023 Halberd continued its groundbreaking work on its path to creating new technology products and safe, yet effective treatments for previously considered incurable or difficult-to-treat diseases. 2nd QUARTER 2023 ACHIEVEMENTS Mississippi State University (MSU) is well on their way in ...

Go to Top